Camber Pharmaceuticals Inc. has recalled approximately 1,105,085 bottles of Losartan Potassium Tablets USP (25 mg, 50 mg, and 100 mg) due to the detection of a chemical impurity called NMBA in the active ingredient. NMBA is a potential human carcinogen that was found during testing, and its presence indicates a deviation from current Good Manufacturing Practices (CGMP). These prescription medications were distributed nationwide in various bottle counts ranging from 30 to 1,000 tablets. Consumers should not stop taking their medication without first consulting a healthcare provider, as the risk of stopping high blood pressure treatment may be greater than the risk of the impurity.
The tablets contain trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), which is classified as a potential human carcinogen. Long-term exposure to levels above acceptable limits may increase the risk of cancer.
Product return for refund and pharmacist consultation.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.